Pharmaceutical Research

, Volume 21, Issue 5, pp 891–894

Oxaliplatin Degradation in the Presence of Chloride: Identification and Cytotoxicity of the Monochloro Monooxalato Complex

  • Elin Jerremalm
  • Mikael Hedeland
  • Inger Wallin
  • Ulf Bondesson
  • Hans Ehrsson


Purpose. To study the degradation of oxaliplatin in chloride media and evaluate the cytotoxicity of oxaliplatin in normal and chloride-deficient medium.

Methods. The products of the reaction of oxaliplatin with chloride were separated on a Hypercarb S column with a mobile phase containing 40% methanol in 0.05 M ammonia and subjected to electrospray ionization mass spectrometry. The cytotoxicity of oxaliplatin in normal and chloride-deficient medium was evaluated by 30-min incubations on human colon adenocarcinoma cells (HT-29).

Results. We identified a new intermediate degradation product, the monochloro monooxalato complex ([Pt(dach)oxCl]) and the final product, the dichloro complex (Pt(dach)Cl2), by liquid chromatography-mass spectrometry. [Pt(dach)oxCl] was found as the negative ion, M, at m/z 431, and the positive ion, [M+2H]+, m/z 433. Pt(dach)Cl2 was found as the negative ion, [M-H], m/z 377, and the positive ion, [M+NH4]+, m/z 396. The fast initial degradation of oxaliplatin can be coupled to the fast formation of [Pt(dach)oxCl]. In the cytotoxic assay, the cell survival was not affected by the chloride levels.

Conclusions. [Pt(dach)oxCl], a new transformation product of oxaliplatin, has been identified. Its in vitro cytotoxic effect does not appear to exceed that of oxaliplatin.

biotransformation HT-29 Pt(dach)Cl2 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. Mani, M. A. Graham, D. B. Bregman, P. Ivy, and S. G. Chaney. Oxaliplatin: a review of evolving concepts. Cancer Invest. 20:246–263 (2002).Google Scholar
  2. 2.
    H. Ehrsson, I. Wallin. and J. Yachnin. Pharmacokinetics of oxaliplatin in humans. Med. Oncol. 19:261–265 (2002).Google Scholar
  3. 3.
    M. A. Graham, G. F. Lockwood, D. Greenslade, S. Brienza, M. Bayssas, and E. Gamelin. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. 6:1205–1218 (2000).Google Scholar
  4. 4.
    P. Allain, O. Heudi, A. Cailleux, A. Le Bouil, F. Larra, M. Boisdron-Celle, and E. Gamelin. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab. Dispos. 28:1379–1384 (2000).Google Scholar
  5. 5.
    F. R. Luo, S. D. Wyrick, and S. G. Chaney. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol. Res. 10:595–603 (1998).Google Scholar
  6. 6.
    P. Videhult, J. Yachnin, E. Jerremalm, R. Lewensohn, and H. Ehrsson. Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin. Cancer Lett. 180:191–194 (2002).Google Scholar
  7. 7.
    J. L. Butour, A. M. Mazard, and J. P. Macquet. Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem. Biophys. Res. Commun. 133:347–353 (1985).Google Scholar
  8. 8.
    U. Frey, J. D. Ranford, and P. J. Sadler. Ring-opening reactions of the anticancer drug carboplatin: NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5′-GMP-N7)] in solution. Inorg. Chem. 32:1333–1340 (1993).Google Scholar
  9. 9.
    S. S. Shord, S. A. Bernard, C. Lindley, A. Blodgett, V. Mehta, M. A. Churchel, M. Poole, S. L. Pescatore, F. R. Luo, and S. G. Chaney. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res. 22:2301–2310 (2002).Google Scholar
  10. 10.
    G. Siebert. The biochemical environment of the mammalian nucleus. Sub-Cell. Biochem. 1:277–292 (1972).Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • Elin Jerremalm
    • 1
  • Mikael Hedeland
    • 2
  • Inger Wallin
    • 1
  • Ulf Bondesson
    • 2
    • 3
  • Hans Ehrsson
    • 1
    • 4
  1. 1.Karolinska PharmacyKarolinska HospitalStockholmSweden
  2. 2.Department of ChemistryNational Veterinary Institute (SVA)UppsalaSweden
  3. 3.Division of Analytical Pharmaceutical ChemistryUppsala UniversityUppsalaSweden
  4. 4.Department of Oncology-PathologyKarolinska InstitutetStockholmSweden

Personalised recommendations